Exploratory Study to Evaluate QR-010 in Subjects With Cystic Fibrosis ΔF508 CFTR Mutation
Status:
Completed
Trial end date:
2016-09-01
Target enrollment:
Participant gender:
Summary
Exploratory proof of concept study to determine whether intranasal administration of QR-010
in subjects with cystic fibrosis, homozygous or compound heterozygous for the ΔF508 mutation,
can increase the function of Cystic Fibrosis Transmembrane Conductance Regulator (CFTR).